interpharma cannot apply for pbs listing of gemcitabine ebewe until it has obtained tga registration of gemcitabine ebewe.
introduction 1 the second respondent (lilly) is registered as proprietor of australian patent no 565856 entitled "difluro nucleoside antivirals".
associate: dated: 21 august 2008 counsel for the applicant: bn caine sc and h rofe solicitor for the applicant: stephens lawyers &amp; consultants counsel for the second respondent: scg burley sc and nr murray solicitor for the respondents: clayton utz date of hearing: 28 july 2008 date of judgment: 21 august 2008 austlii: copyright policy | disclaimers | privacy policy | feedback url: http://www.austlii.edu.au/au/cases/cth/fca/2008/1283.html